Medtronic Sets MiniMed Split-Off Exchange Ratio at 4.5939 Upper Limit
Medtronic plc on October 7, 2026 announced the final exchange ratio of 4.5939 shares of MiniMed Group, Inc. common stock for each Medtronic ordinary share validly tendered and accepted in its split-off exchange offer, fixing the ratio at the offer’s…
Abbott CardioMEMS Wins FDA Approval for Patient-Facing App Features
Abbott announced on Oct. 5, 2026 that the U.S. Food and Drug Administration has approved updates to the CardioMEMS HF System that enable new patient-facing capabilities through the company’s CardioGuide HF App. For the first time, care teams can allow…
GE HealthCare Agrees to Buy SOFIE Biosciences for $945 Million
GE HealthCare has agreed to acquire SOFIE Biosciences, a U.S. contract manufacturer of positron emission tomography (PET) radiopharmaceuticals, from Trilantic North America for $945 million in cash, GE HealthCare announced on October 5, 2026. GE HealthCare said it expects the…
AMA Approves Category I CPT Codes for Two Medtronic Device Procedures
Medtronic plc announced on October 1, 2026, that the American Medical Association approved new Category I Current Procedural Terminology (CPT) codes for procedures associated with two of its technologies: the Altaviva implantable tibial neuromodulation device, used to treat urge urinary…
Medtronic Wins FDA Clearance and CE Mark for Affera Prism-2 Software
Medtronic plc announced on September 30, 2026, that it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for the latest version of its Affera Prism-2 Mapping Software, along with a separate CE Mark for the PulseSelect ProxBox…
FDA Grants 510(K) Clearance to Tempus ECG-MR Mitral Regurgitation AI
Tempus AI, Inc. said in a September 28, 2026 announcement that it received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an artificial intelligence product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated…
Abbott to Pay $385 Million to Settle DOJ Infant Formula Recall Claims
Abbott announced on September 14, 2026, that it has reached an agreement to pay $385 million to resolve a previously disclosed U.S. Department of Justice investigation and lawsuit, as well as lawsuits filed by certain relators and the Attorneys General…
Medtronic Opens MiniMed Split-Off Exchange Offer With 7% Discount
Medtronic plc announced on September 14, 2026 that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group, Inc. , its former Diabetes business. Through the offer, Medtronic shareholders can exchange their…
Abbott’s Dual-Energy Ablation Catheter Cleared by FDA for Complex AFib
Abbott said on September 8, 2026, that the U.S. Food and Drug Administration has approved its TactiFlex Duo Ablation Catheter, Sensor Enabled, for treating patients with challenging cases of atrial fibrillation, clearing a device that combines pulsed field ablation and…
Medtronic Raises Fiscal 2027 Guidance on 13.7% Revenue Growth
Medtronic plc on September 1, 2026, reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026, posting worldwide revenue of $9.756 billion, an increase of 13.7% as reported and 13.7% on an organic basis.…
Medtronic Announces $700 Million Cornerstone Robotics Partnership
Medtronic plc announced on September 1, 2026, a strategic partnership with Cornerstone Robotics, a surgical robotics company focused on minimally invasive surgery, structured as an approximately $700 million investment that includes rights to distribute Cornerstone Robotics’ Sentire surgical system in…
Stryker to Buy ZuriMED, Adding FiberLocker to Shoulder Portfolio
By Elena Rossi Stryker announced on August 31, 2026 that it has signed a definitive agreement to acquire ZuriMED, a privately held company that develops the FiberLocker System, a commercialized technology for rotator cuff augmentation. According to the announcement from…
Abbott Amulet 360 Wins CE Mark in Fourth Electrophysiology Approval
Abbott has received a CE Mark for its Amulet 360 left atrial appendage occluder, clearing the next-generation stroke-prevention device for sale in Europe and extending a run of electrophysiology approvals that has now reached four in just over a year.…
Abbott Wins FDA Authorization for Libre Duo 10 Day Glucose-Ketone Sensor
Abbott received U.S. Food and Drug Administration authorization on August 25, 2026, for Libre Duo 10 Day, a single wearable sensor that continuously tracks both glucose and ketones, with a U.S. commercial launch planned before the end of the year.…
Abbott Settles Preterm Formula Claims for $670 Million
Abbott Laboratories has agreed to pay approximately $670 million to resolve a $495 million jury verdict over its specialty formulas for preterm infants plus necrotizing enterocolitis claims covering roughly 2,000 additional infants, the company announced on August 20, 2026 and…
